408 related articles for article (PubMed ID: 23103177)
1. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R
Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312
[TBL] [Abstract][Full Text] [Related]
3. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.
Heemskerk D; Day J; Chau TT; Dung NH; Yen NT; Bang ND; Merson L; Olliaro P; Pouplin T; Caws M; Wolbers M; Farrar J
Trials; 2011 Feb; 12():25. PubMed ID: 21288325
[TBL] [Abstract][Full Text] [Related]
4. Intensified intravenous rifampicin in tuberculous meningitis.
Brouwer MC; van de Beek D
Lancet Infect Dis; 2013 Jan; 13(1):2-3. PubMed ID: 23103176
[No Abstract] [Full Text] [Related]
5. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
[TBL] [Abstract][Full Text] [Related]
6. Rifampicin and moxifloxacin for tuberculous meningitis.
Ukwaja KN; Onyedum CC
Lancet Infect Dis; 2013 Jul; 13(7):569-70. PubMed ID: 23809223
[No Abstract] [Full Text] [Related]
7. Rifampicin and moxifloxacin for tuberculous meningitis.
Akkerman O; Pranger A; van Altena R; van der Werf T; Alffenaar JW
Lancet Infect Dis; 2013 Jul; 13(7):568-9. PubMed ID: 23809221
[No Abstract] [Full Text] [Related]
8. Rifampicin and moxifloxacin for tuberculous meningitis--authors' reply.
Ruslami R; Ganiem AR; Aarnoutse RE; van Crevel R;
Lancet Infect Dis; 2013 Jul; 13(7):570. PubMed ID: 23809224
[No Abstract] [Full Text] [Related]
9. Comparative evaluation of intensified short course regimen and standard regimen for adults TB meningitis: a protocol for an open label, multi-center, parallel arms, randomized controlled superiority trial (INSHORT trial).
Inbaraj LR; Manesh A; Ponnuraja C; Bhaskar A; Srinivasalu VA; Daniel BD
Trials; 2024 May; 25(1):294. PubMed ID: 38693583
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
11. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.
Kalita J; Misra UK; Prasad S; Bhoi SK
J Antimicrob Chemother; 2014 Aug; 69(8):2246-51. PubMed ID: 24752957
[TBL] [Abstract][Full Text] [Related]
13. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.
Pouplin T; Bang ND; Toi PV; Phuong PN; Dung NH; Duong TN; Caws M; Thwaites GE; Tarning J; Day JN
BMC Infect Dis; 2016 Apr; 16():144. PubMed ID: 27039088
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
[TBL] [Abstract][Full Text] [Related]
15. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
[TBL] [Abstract][Full Text] [Related]
16. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
Ruslami R; Fregonese F; Apriani L; Barss L; Bedingfield N; Chiang V; Cook VJ; Fisher D; Flores E; Fox GJ; Johnston J; Lim RK; Long R; Paulsen C; Nguyen TA; Nhung NV; Gibson D; Valiquette C; Benedetti A; Menzies D
Lancet Respir Med; 2024 Jun; 12(6):433-443. PubMed ID: 38552659
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
18. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis.
Heemskerk AD; Bang ND; Mai NT; Chau TT; Phu NH; Loc PP; Chau NV; Hien TT; Dung NH; Lan NT; Lan NH; Lan NN; Phong le T; Vien NN; Hien NQ; Yen NT; Ha DT; Day JN; Caws M; Merson L; Thinh TT; Wolbers M; Thwaites GE; Farrar JJ
N Engl J Med; 2016 Jan; 374(2):124-34. PubMed ID: 26760084
[TBL] [Abstract][Full Text] [Related]
19. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Ahmad Z; Tyagi S; Minkowski A; Peloquin CA; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2013 Jul; 188(1):97-102. PubMed ID: 23593945
[TBL] [Abstract][Full Text] [Related]
20. [Antibiotic regimens in tuberculous meningitis].
Rokstad IS
Tidsskr Nor Laegeforen; 2013 Feb; 133(3):278. PubMed ID: 23560288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
